Emergent BioSolutions Inc. has secured a $17 million contract modification to supply TEMBEXA® (brincidofovir) oral suspension, a smallpox antiviral, through the Biomedical Advanced Research and Development Authority (BARDA). This contract is part of an ongoing 10-year agreement with the U.S. Department of Health and Human Services $(HHS)$, aimed at strengthening the U.S. supply chain for critical health countermeasures. The contract follows FDA approval for the scale-up of manufacturing this formulation, which is particularly beneficial for patients who face difficulties swallowing due to age or health conditions. Emergent's collaboration with BARDA underscores the importance of maintaining a steady supply of medical countermeasures to protect vulnerable populations in the event of a smallpox outbreak.